590 related articles for article (PubMed ID: 25387892)
1. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y
PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy.
Kim YH; Choi BK; Oh HS; Kang WJ; Mittler RS; Kwon BS
Mol Cancer Ther; 2009 Feb; 8(2):469-78. PubMed ID: 19190115
[TBL] [Abstract][Full Text] [Related]
4. Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.
Bartkowiak T; Jaiswal AR; Ager CR; Chin R; Chen CH; Budhani P; Ai M; Reilley MJ; Sebastian MM; Hong DS; Curran MA
Clin Cancer Res; 2018 Mar; 24(5):1138-1151. PubMed ID: 29301830
[No Abstract] [Full Text] [Related]
5. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
[TBL] [Abstract][Full Text] [Related]
6. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
Front Immunol; 2020; 11():577. PubMed ID: 32391001
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.
McKee SJ; Doff BL; Soon MS; Mattarollo SR
Cancer Immunol Res; 2017 Mar; 5(3):191-197. PubMed ID: 28115358
[TBL] [Abstract][Full Text] [Related]
8. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses.
Menk AV; Scharping NE; Rivadeneira DB; Calderon MJ; Watson MJ; Dunstane D; Watkins SC; Delgoffe GM
J Exp Med; 2018 Apr; 215(4):1091-1100. PubMed ID: 29511066
[TBL] [Abstract][Full Text] [Related]
9. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
10. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
[TBL] [Abstract][Full Text] [Related]
11. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
12. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
Williams JB; Horton BL; Zheng Y; Duan Y; Powell JD; Gajewski TF
J Exp Med; 2017 Feb; 214(2):381-400. PubMed ID: 28115575
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.
Quetglas JI; Dubrot J; Bezunartea J; Sanmamed MF; Hervas-Stubbs S; Smerdou C; Melero I
Mol Ther; 2012 Sep; 20(9):1664-75. PubMed ID: 22735380
[TBL] [Abstract][Full Text] [Related]
14. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
15. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
[TBL] [Abstract][Full Text] [Related]
17. EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8
Stairiker CJ; Pfister SX; Hendrickson E; Yang W; Xie T; Lee C; Zhang H; Dillon C; Thomas GD; Salek-Ardakani S
Front Immunol; 2021; 12():770080. PubMed ID: 34925340
[TBL] [Abstract][Full Text] [Related]
18. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
